文献速递肝病

肝脏白细胞免疫球蛋白样受体B4(LILRB4)通过SHP1-TRAF6通路减轻非酒精性脂肪性肝病

Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway.
PubMed 文献 · Hepatology · 2018-02-07

该研究通过功能获得与功能缺失实验发现,白细胞免疫球蛋白样受体B4(LILRB4)是非酒精性脂肪性肝病(NAFLD)的负调控因子;肝细胞特异性敲除LILRB4加重高脂饮食诱导的胰岛素抵抗、糖代谢失衡、肝脏脂质蓄积和系统性炎症,而过表达则表现相反表型;机制上LILRB4招募SHP1抑制TRAF6泛素化及下游NF-κB和MAPK级联活化;在ob/ob小鼠中过表达LILRB4可大部分逆转肝脏脂肪变性、炎症和代谢紊乱。

要点

  • 肝细胞特异性敲除LILRB4加重高脂饮食小鼠的胰岛素抵抗、糖代谢失衡、肝脏脂质蓄积和系统性炎症。
  • 肝细胞过表达LILRB4在相应对照比较中表现出与敲除小鼠完全相反的表型。
  • LILRB4通过招募SHP1抑制TRAF6泛素化及NF-κB和MAPK级联活化。

核心结论

  • 靶向肝脏LILRB4以提高其表达或活化是治疗NAFLD及相关肝脏和代谢疾病的一种有前景的策略。

研究设计与样本

  • 研究采用功能获得与功能缺失方法,在 mice 中构建肝细胞特异性LILRB4敲除(LILRB4-HKO)模型,并与相应对照比较。
  • 在肝细胞中过表达LILRB4,并与相应对照比较。
  • 在NAFLD遗传模型ob/ob小鼠中过表达LILRB4。

主要发现

  • LILRB4-HKO小鼠在高脂饮食诱导下胰岛素抵抗、糖代谢失衡、肝脏脂质蓄积和系统性炎症加重。
  • 肝细胞过表达LILRB4在相应对照比较中表现出与LILRB4-HKO小鼠完全相反的表型。
  • 机制上LILRB4招募SHP1抑制TRAF6泛素化,进而使核因子κB和丝裂原活化蛋白激酶级联失活。
  • 在ob/ob小鼠中过表达LILRB4可大部分逆转固有的肝脏脂肪变性、炎症和代谢紊乱。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent liver pathology characterized by hepatic steatosis and commonly accompanied by systematic inflammation and metabolic disorder. Despite an accumulating number of studies, no pharmacological strategy is available to treat this condition in the clinic. In this study, we applied extensive gain- and loss-of-function approaches to identify the key immune factor leukocyte immunoglobulin-like receptor B4 (LILRB4) as a negative regulator of NAFLD. The hepatocyte-specific knockout of LILRB4 (LILRB4-HKO) exacerbated high-fat diet-induced insulin resistance, glucose metabolic imbalance, hepatic lipid accumulation, and systematic inflammation in mice, whereas LILRB4 overexpression in hepatocytes showed a completely opposite phenotype relative to that of LILRB4-HKO mice when compared with their corresponding controls. Further investigations of molecular mechanisms demonstrated that LILRB4 recruits SHP1 to inhibit TRAF6 ubiquitination and subsequent inactivation of nuclear factor kappa B and mitogen-activated protein kinase cascades. From a therapeutic perspective, the overexpression of LILRB4 in a genetic model of NAFLD, ob/ob mice, largely reversed the inherent hepatic steatosis, inflammation, and metabolic disorder. CONCLUSION: Targeting hepatic LILRB4 to improve its expression or activation represents a promising strategy for the treatment of NAFLD as well as related liver and metabolic diseases. (Hepatology 2018;67:1303-1319).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lu Y, Jiang Z, Dai H, et al. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway. Hepatology. 2018. PMID: 29091299. doi:10.1002/hep.29633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。